Malignancy grade-dependent expression of K+-channel subtypes in human prostate cancer

Journal of Pharmacological Sciences

Volumn 109, Issue 1, 2009, Pages 148-151

  Ohya, Susumu ^a   Kimura, Kazunori ^b   Niwa, Satomi ^a   Ohno, Akitoshi ^a   Kojima, Yoshiyuki ^c   Sasaki, Shoichi ^c   Kohri, Kenjiro ^c   Imaizumi, Yuji ^a  

^a Department of Molecular and Cellular Pharmacology ^*  (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

K+ channel; Prostate cancer; Tumor marker

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM CHANNEL 1.1; CALCIUM ACTIVATED POTASSIUM CHANNEL 3.1; POTASSIUM CHANNEL; POTASSIUM CHANNEL K2P1; POTASSIUM CHANNEL K2P3; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL KV4.3; TWO PORE DOMAIN POTASIUM CHANNEL; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION;

EID: 58649110843     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08208SC     Document Type: Article

References (15)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
2. Sweat SD, Bergrtralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol. 2002;168:525-529.
3. + channel in Jurkat T-lymphocytes. J Pharmacol Sci. 2007;104:94-98.
4. 2+-entry pathway in t-BBEC 117 cell-line derived from bovine brain endothelial cell. J Pharmacol Sci. 2007;104:103-107.
5. Schönherr R. Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol. 2005;205:175-184.
6. Prevarskaya N, Skryma R, Bidaux G, Flourakis M, Shuba Y. Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ. 2007;14:1295-1304.
7. Kunzelmann K. Ion channels and cancer. J Membr Biol. 2005;205:159-173.
8. Stuhmer W, Alves F, Hartung F, Zientkowska M, Pardo LA. Potassium channels as tumour markers. FEBS Lett. 2006;580:2850-2852.
9. + channels in cardiac mitochondria. Am J Physiol Heart Circ Physiol. 2005;289:H1635-H1642.
10. V1.3 potassium channel expression in human prostate cancer. J Membr Biol. 2006;214:99-102.
11. + channel in effector memory T cells as new target for MS. J Clin Invest. 2003;111:1703-1713.
12. + channels: role in apoptosis and tumorigenesis. Pflugers Arch. 2004;448:261-273.
13. Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H, et al. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J. 2008;27:792-803.
14. Guan M, Chen Y. Aberrant expression of ΔNp73 in benign and malignenet tumours of the prostate: correlation with Gleason score. J Clin Pathol. 2005;58:1175-1179.
15. Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC, Mihatsch MJ, et al. KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene. 2007;26:2525-2534.